Carbon dioxide (CO₂) emissions from anthropogenic origin have been identified as one of the main contributors to the current global warming that earth is experiencing. The International Panel on Climate Change predicts that in 2100 the concentration of CO₂ in the atmosphere will be about 570 ppm, which will promote an increase of 1.5 °C in the average atmospheric temperature. These concerns have triggered the development of CO₂ capture technologies to mitigate these emissions.

Solid acid catalysts appeared as a safer alternative to conventional liquid phase acids, namely HF and H₂SO₄, and since the 1940s have dominated relevant industry fields such as petrochemicals and oil refining. Zeolites are among the most widely used solid acid catalysts because they contain Brønsted and Lewis acid sites, shape selectivity and are thermally stable.

Approximately 40% of novel active pharmaceutical ingredients (APIs) are rejected by the pharmaceutical industry due to low bioavailability. To address this, there are several strategies to increase the bioavailabitity of a given API: developing carrier systems to increase bioavailability and defend drug molecules against degradation or increasing the solubility through the production of multicomponent systems are two examples. By developing a variety of drug delivery systems (DDSs) it is possible to better control the pharmacokinetics, pharmacodynamics, toxicity, immunogenicity and efficacy of drugs.